ClinicalTrials.Veeva

Menu
U

Utah Kidney Research Institute | Salt Lake City, UT

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CCX140-B
RG-012
Lixivaptan
Povetacicept
GFB-887
BI 764198
Vicadrostat
Retatrutide
DMX-200
Mezagitamab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 14 total trials
Locations recently updated

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complex...

Enrolling
Kidney Disease
Drug: Mezagitamab
Drug: Placebo

DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit...

Enrolling
FSGS
Drug: DMX-200
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO...

Enrolling
Primary IgA Nephropathy
Drug: Placebo
Drug: Sefaxersen (RO7434656)

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is t...

Enrolling
Focal Segmental Glomerulosclerosis
Drug: Placebo
Drug: BI 764198

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication...

Enrolling
Chronic Kidney Disease
Drug: Vicadrostat
Drug: Empagliflozin

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserv...

Active, not recruiting
Immunoglobulin A Nephropathy
Drug: Placebo (matched to Povetacicept)
Drug: Povetacicept
Status recently updated

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Active, not recruiting
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy

Active, not recruiting
Immunoglobulin A Nephropathy
Drug: Sibeprenlimab 400 mg
Drug: Placebo

Trial sponsors

Amgen logo
Boehringer Ingelheim logo
D
Genzyme logo
G
Lilly logo
Otsuka logo
P
Roche logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems